These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36281062)

  • 1. Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates.
    Ramakrishnan V; Friedrich C; Witt C; Sheehan R; Pryor M; Atwal JK; Wildsmith K; Kudrycki K; Lee SH; Mazer N; Hofmann C; Fuji RN; Jin JY; Ramanujan S; Dolton M; Quartino A
    CPT Pharmacometrics Syst Pharmacol; 2023 Jan; 12(1):62-73. PubMed ID: 36281062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease.
    Geerts H; Walker M; Rose R; Bergeler S; van der Graaf PH; Schuck E; Koyama A; Yasuda S; Hussein Z; Reyderman L; Swanson C; Cabal A
    CPT Pharmacometrics Syst Pharmacol; 2023 Apr; 12(4):444-461. PubMed ID: 36632701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Madrasi K; Das R; Mohmmadabdul H; Lin L; Hyman BT; Lauffenburger DA; Albers MW; Rissman RA; Burke JM; Apgar JF; Wille L; Gruenbaum L; Hua F
    Alzheimers Dement; 2021 Sep; 17(9):1487-1498. PubMed ID: 33938131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive Immunotherapies Targeting Amyloid-
    Marković M; Milošević J; Wang W; Cao Y
    Mol Pharmacol; 2023 Dec; 105(1):1-13. PubMed ID: 37907353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic Modeling of Soluble Aβ Dynamics and Target Engagement in the Brain by Anti-Aβ mAbs in Alzheimer's Disease.
    Ferl GZ; Fuji RN; Atwal JK; Sun T; Ramanujan S; Quartino AL
    Curr Alzheimer Res; 2020; 17(4):393-406. PubMed ID: 32116192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
    Lu D; Dou F; Gao J
    Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid.
    Lin L; Hua F; Salinas C; Young C; Bussiere T; Apgar JF; Burke JM; Kandadi Muralidharan K; Rajagovindan R; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Mar; 11(3):362-372. PubMed ID: 35029320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of monomeric amyloid-β in cognitive performance in Alzheimer's disease: Insights from clinical trials with secretase inhibitors and monoclonal antibodies.
    Imbimbo BP; Ippati S; Watling M; Imbimbo C
    Pharmacol Res; 2023 Jan; 187():106631. PubMed ID: 36586644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target?
    Watt AD; Crespi GA; Down RA; Ascher DB; Gunn A; Perez KA; McLean CA; Villemagne VL; Parker MW; Barnham KJ; Miles LA
    Acta Neuropathol; 2014; 127(6):803-10. PubMed ID: 24803227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
    Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
    Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials.
    Tian Hui Kwan A; Arfaie S; Therriault J; Rosa-Neto P; Gauthier S
    Dement Geriatr Cogn Disord; 2020; 49(4):334-348. PubMed ID: 33321511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical Appraisal of Amyloid Lowering Agents in AD.
    Decourt B; Boumelhem F; Pope ED; Shi J; Mari Z; Sabbagh MN
    Curr Neurol Neurosci Rep; 2021 Jun; 21(8):39. PubMed ID: 34110536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis.
    Liao F; Hori Y; Hudry E; Bauer AQ; Jiang H; Mahan TE; Lefton KB; Zhang TJ; Dearborn JT; Kim J; Culver JP; Betensky R; Wozniak DF; Hyman BT; Holtzman DM
    J Neurosci; 2014 May; 34(21):7281-92. PubMed ID: 24849360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Investigation of Gantenerumab and Crenezumab Recognition of Aβ Fibrils in Alzheimer's Disease Brain Tissue.
    Chen Y; Wei G; Zhao J; Nussinov R; Ma B
    ACS Chem Neurosci; 2020 Oct; 11(20):3233-3244. PubMed ID: 32991803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.